Alumis Inc. is drawing attention with a major share sale and bullish analyst forecasts. The firm aims to fund its immune ...

The company said that envudeucitinib met all the primary and secondary endpoints in both trials. ・Across both trials, the ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

Foresite Capital Fund VI, L.P. holds 4,247,670 shares, Labs Co-Invest V, LLC holds 194,459 shares, Foresite Labs Fund I, L.P. holds 1,960,337 shares, and Foresite Labs Affiliates 2021, LLC holds 1,176 ...

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.